ClinicalTrials.gg

Program

FXS6837

A development code. Also written as “FXS6837 Capsule”, “FXS6837 Dose 1” and “FXS6837 Dose 2”.

In Fosun Pharma's pipeline, CFB. Its studies are mostly in Hemoglobinuria, Paroxysmal, led by Fosun Pharma.

Furthest: phase 3, since Jul 22, 20264 company-led studies, 4 open or runningNext primary completion: Sep 12, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma44 open or runningphase 3since Jul 22, 2026Mar 15, 2026Sep 12, 2027phase 2 · NCT07502638
  • Named in Fosun Pharma’s own pipeline as FXS6837 (CFB), phase 2, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 15, 2026First study: phase 2 study in IgANFirst studyNCT07502638 · 60 planned · China
  2. Jul 22, 2026Phase 3 study in Hemoglobinuria, ParoxysmalPhase 3 reachedNCT07747090 · 90 planned · China
  3. Aug 2, 2026Phase 2 study in Primary IgANNCT07750665 · 60 planned · China
  4. Oct 13, 2026Phase 3 study in Hemoglobinuria, ParoxysmalNCT07914894 · 20 planned · China

Ahead

  1. Sep 12, 2027Primary completion: phase 2 study in IgANNCT07502638
  2. May 5, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07747090
  3. May 17, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07914894
  4. Nov 13, 2029Primary completion: phase 2 study in Primary IgANNCT07750665

TargetBeta

“CFB”the company's pipeline, read by Claude · source

Other programs on CFB

ProgramCompanyFurthest phaseStudies
iptacopanruleNovartisphase 325
HRS-5965Jiangsu HengRui Medicinephase 314
NTQ5082ruleSino Biopharmaceuticalphase 36
sefaxersenHoffmann-La Rochephase 31
HS-10542Hansoh Pharmaceutical Groupphase 23
FWY003Novartisphase 21
SAR446597Sanofiphase 21

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07914894Hemoglobinuria, Paroxysmal · China3Not yet recruitingMay 17, 202820
NCT07750665Primary IgAN · China2Not yet recruitingNov 13, 202960
NCT07747090Hemoglobinuria, Paroxysmal · China3Not yet recruitingMay 5, 202890
NCT07502638IgAN · China2Not yet recruitingSep 12, 202760

How it is read

Names in the registry

  • “FXS6837 Capsule”, 3 entries
  • “FXS6837 Dose 1”, 1 entry
  • “FXS6837 Dose 2”, 1 entry

Codes read as this program: FXS6837.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.